Market Place
Sourcing Support
Natco shares rise 4% order in US patent case over generic Ozempic
07 Oct 2024 //
MONEYCONTROL
Natco Pharma acquires 40 million shares in eGenesis Inc
04 Sep 2024 //
ECONOMICTIMES
Natco Pharma Q1 profit up 59 pc at Rs 668 cr
12 Aug 2024 //
ECONOMICTIMES
Natco Pharma on Health Canada Inspection list
02 May 2024 //
HEALTH CANADA
USFDA pulls up Natco Pharma for several violations at Telangana plant
22 Apr 2024 //
BUSINESS STANDARD
Enforcement Report - Week of April 17, 2024
17 Apr 2024 //
FDA
FDA hits Natco with warning letter over India facility, suspends product shipments to US
17 Apr 2024 //
ENDPTS
Natco Pharma Receives FDA Warning Letter
17 Apr 2024 //
FDA
Lupin, Glenmark recall drugs in US market: USFDA
10 Apr 2024 //
MONEYCONTROL
Natco Pharma gets USFDA warning letter for Kothur plant
09 Apr 2024 //
BSEINDIA
Natco Pharma gets warning letter from USFDA for Telangana plant
08 Apr 2024 //
ECONOMIC TIMES
Enforcement Report - Week of February 14, 2024
14 Feb 2024 //
FDA
NATCO invests US$ 2 million in Cellogen Therapeutics
18 Jan 2024 //
INDIAN PHARMA POST
Natco Pharma Completes Transition of DASH Pharmaceuticals into Natco Pharma
02 Jan 2024 //
BUSINESSWIRE
Natco Pharma and Breckenridge dismissed from antitrust lawsuit
21 Dec 2023 //
INDIAN PHARMA POST
Operations disrupted at NATCO Pharma`s Manali, Chennai factory
08 Dec 2023 //
INDIAN PHARMA POST
Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
15 Nov 2023 //
INDIAN PHARMA POST
FDA slams Natco Pharma with Form 483 over sanitary, other issues
06 Nov 2023 //
FIERCE PHARMA
FDA Issues Form 483 to NATCO Pharma Limited
01 Nov 2023 //
FDA
Natco Pharma shares down as USFDA issues 8 observations for Hyderabad unit
20 Oct 2023 //
MONEY CONTROL
Natco Pharma, others sued in US for generic cancer drug
08 Sep 2023 //
ECONOMIC TIMES
Natco`s Generic Tipiracil HCL, Trifluridine Receives Approval in the U.S.
13 Jun 2023 //
FDA
India`s Natco Pharma invests $3 M to set up subsidiary in Indonesia
21 Apr 2023 //
BIOSPECTRUM ASIA
Natco Pharma launches additional strengths of generic version of Revlimid in US
10 Mar 2023 //
ECONOMIC TIMES
Teva and Natco Announce Launch of additional strengths for Revlimid
09 Mar 2023 //
BUSINESSWIRE
Natco Pharma submits application with USFDA for generic cancer drug
13 Feb 2023 //
ECONOMIC TIMES
Natco Pharma Vizag facility gets two USFDA observations
06 Feb 2023 //
BUSINESS STANDARD
HC reserves order on Natco`s plea over patent for Novartis drug
11 Jan 2023 //
ECONOMIC TIMES
Zhongchao Announces Drug Distributorship in China of Indian Drugs of Natco
04 Jan 2023 //
PR NEWSWIRE
Top Novartis cardiac drug to go off patent
03 Dec 2022 //
ECONOMICTIMES
NATCO launches Chlorantraniliprole combination agro products in India
04 Oct 2022 //
INDIANPHARMAPOST
Natco Cancer centre adopts Dozee, Contactless Continuous Remote Patient
12 Sep 2022 //
PHARMABIZ
NATCO cancer centre adopts Dozee`s RPM technology for cancer patients
09 Sep 2022 //
ECONOMIC TIMES
NATCO Pharma to sell stake in Nativita and assets of Pharma division
05 Sep 2022 //
INDIAINFOLINE
Natco Pharma`s partner Breckenridge gets FDA nod for prostate cancer drug
25 Jul 2022 //
ECONOMIC TIMES
J&J, Momenta Pharma file patent infringement lawsuit against Natco, Mylan
26 May 2022 //
BUSINESS-STANDARD
Natco, Biophore Pharma get nod to manufacture, market molnupiravir
20 Jan 2022 //
THEHINDUBUSINESSLINE
Natco Pharma signs pact with MPP to sell Molnupiravir capsules
20 Jan 2022 //
ECONOMIC TIMES
Natco acquires Dash Pharma for $18 million
04 Jan 2022 //
TIMESOFINDIA
Natco Pharma plans to launch Molnupiravir capsules this week
29 Dec 2021 //
EXPRESSPHARMA
Natco Pharma to launch Molnupiravir capsules this week for treatment of COVID-19
28 Dec 2021 //
ECONOMICTIMES
India’s NATCO Positioned to Acquire New Jersey Pharma Sales Operation Dash
17 Dec 2021 //
TRIALSITENEWS
Natco Pharma to acquire Dash Pharmaceuticals
17 Dec 2021 //
PHARMABIZ
NATCO Pharma launches Tipanat tablets for advanced colorectal, gastric cancer
23 Nov 2021 //
INDIAINFOLINE
Natco Pharma launches Tipanat tabs for colorectal and gastric cancer
18 Nov 2021 //
PHARMABIZ
Delhi HC restrains generic firms from making, selling patent drug of Novartis
03 Nov 2021 //
ECONOMICTIMES
Natco and Hetero awaits approval from DCGI on molnupiravir
30 Oct 2021 //
PHARMABIZ
Breckenridge Pharma launches generic Afinitor in US market
01 Oct 2021 //
PHARMABIZ
Dr Reddy`s, Natco Pharma Launch Generic Cancer Drug In Canada
02 Sep 2021 //
BUSINESS STANDARD
Natco Pharma (Canada) Inc. announces the launch of (Pr)NAT-LENALIDOMIDE Capsules
01 Sep 2021 //
NEWSWIRE
AbbVie Says Court Rules Imbruvica Patents Valid in Generic Challenge
21 Aug 2021 //
MORNING STAR
Natco Pharma stock dips more than 4% over verdict on patent litigation
20 Aug 2021 //
INDIAINFOLINE
Pharma shares under pressure; Aurobindo, Wockhardt, Hikal, Natco down 6%
20 Aug 2021 //
BUSINESS STANDARD
NATCO transfers Lenalidomide ANDA to Arrow
03 Aug 2021 //
BUSINESS-STANDARD
Breckenridge Announces Approval of its ANDA for Carfilzomib Intravenous Powder
16 Jun 2021 //
BIOSPACE
NATCO receives approval for Carfilzomib Vials ANDA
14 Jun 2021 //
BUSINESS STANDARD
Natco Pharma surges 20%, hits new high on USFDA nod for cancer drug
24 May 2021 //
BUSINESS-STANDARD
Natco Pharma Initiates Molnupiravir Phase 3 Trials
21 May 2021 //
BUSINESSWORLD
NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India
17 May 2021 //
PRESS RELEASE
Covid drug: Natco eyes patent waiver
06 May 2021 //
ECONOMICTIMES
